Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ROIV, Apogee Therapeutics, SYRE, XENE, ERAS, and represent 25.75% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: TRAX (+$41M), ROIV (+$34M), ARKG (+$32M), AVTX (+$29M), LLY (+$24M), INSM (+$18M), BLTE (+$15M), IDYA (+$15M), ODTX (+$14M), OMER (+$13M).
- Started 23 new stock positions in OMER, FTH, NMRA, AMLX, IDYA, BHVN, ASND, RACC, SPRB, JATT. ODTX, TRAX, Celcuity, EVMN, EIKN, AMAN, COAG, ENGN, ARKG, ASMB, SMMT, LLY, BOLD.
- Reduced shares in these 10 stocks: , Centessa Pharmaceuticals (-$56M), ACLX (-$42M), Apogee Therapeutics (-$40M), Teva Pharmaceutical Industries (-$35M), TERN (-$30M), Ascendis Pharma A S (-$22M), BMY (-$18M), CYTK (-$13M), COGT (-$12M).
- Sold out of its positions in ACLX, Ascendis Pharma A S, BBIO, BMY, CELC, Celcuity, Centessa Pharmaceuticals, CGON, CORT, Engene Holdings. IBRX, Kezar Life Sciences, NVO, SPY, TERN, Wave Life Sciences.
- Affinity Asset Advisors was a net seller of stock by $-101M.
- Affinity Asset Advisors has $2.2B in assets under management (AUM), dropping by 14.26%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csvPortfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 110 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Roivant Sciences SHS (ROIV) | 6.0 | $133M | +33% | 3.8M | 35.39 |
|
| Apogee Therapeutics | 5.9 | $131M | -23% | 987k | 132.73 |
|
| Spyre Therapeutics Com New (SYRE) | 5.1 | $114M | 1.3M | 88.78 |
|
|
| Xenon Pharmaceuticals (XENE) | 4.4 | $96M | -4% | 1.6M | 60.36 |
|
| Erasca (ERAS) | 4.3 | $96M | 5.3M | 18.32 |
|
|
| Alkermes SHS (ALKS) | 3.3 | $72M | 1.4M | 52.40 |
|
|
| Insmed Com Par $.01 (INSM) | 3.1 | $69M | +35% | 650k | 106.62 |
|
| Moderna Put Option (MRNA) | 3.1 | $68M | +21% | 975k | 70.03 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.8 | $62M | +8% | 185k | 334.79 |
|
| Oruka Therapeutics (ORKA) | 2.5 | $56M | +18% | 590k | 95.17 |
|
| Anaptysbio Inc Common (ANAB) | 2.5 | $56M | -12% | 826k | 67.50 |
|
| Avalo Therapeutics Com New (AVTX) | 2.4 | $54M | +116% | 2.9M | 18.48 |
|
| Cytokinetics Com New (CYTK) | 2.1 | $47M | -21% | 550k | 85.19 |
|
| Revolution Medicines (RVMD) | 2.1 | $47M | +25% | 250k | 187.28 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.0 | $44M | -18% | 330k | 133.26 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 1.8 | $41M | NEW | 2.0M | 20.12 |
|
| Dianthus Therapeutics (DNTH) | 1.8 | $39M | 400k | 97.48 |
|
|
| Sutro Biopharma Com Shs (STRO) | 1.8 | $39M | +9% | 1.2M | 33.20 |
|
| Nuvalent Inc-a (NUVL) | 1.5 | $34M | -8% | 275k | 123.50 |
|
| Trevi Therapeutics (TRVI) | 1.5 | $34M | -9% | 1.8M | 18.65 |
|
| Ark Etf Tr Genomic Rev Etf Call Option (ARKG) | 1.4 | $32M | NEW | 750k | 42.06 |
|
| Ovid Therapeutics (OVID) | 1.2 | $27M | -4% | 10M | 2.69 |
|
| Lexeo Therapeutics (LXEO) | 1.2 | $27M | +14% | 5.8M | 4.66 |
|
| Celldex Therapeutics Com New (CLDX) | 1.2 | $26M | +40% | 700k | 37.21 |
|
| Belite Bio Sponsored Ads (BLTE) | 1.1 | $25M | +153% | 165k | 153.99 |
|
| Enliven Therapeutics (ELVN) | 1.1 | $25M | -14% | 500k | 50.75 |
|
| Forte Biosciences Com New | 1.1 | $24M | +13% | 1.1M | 21.25 |
|
| Eli Lilly & Co. Call Option (LLY) | 1.1 | $24M | NEW | 20k | 1199.43 |
|
| Nurix Therapeutics (NRIX) | 1.1 | $24M | 968k | 24.26 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 1.0 | $22M | +70% | 850k | 26.39 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.0 | $22M | -27% | 40k | 536.95 |
|
| Protagonist Therapeutics (PTGX) | 1.0 | $21M | 172k | 122.58 |
|
|
| Mineralys Therapeutics (MLYS) | 0.9 | $20M | 750k | 26.98 |
|
|
| Relay Therapeutics (RLAY) | 0.9 | $20M | +162% | 1.1M | 18.71 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.9 | $19M | +187% | 2.5M | 7.73 |
|
| Jade Biosciences Com New (JBIO) | 0.8 | $19M | +31% | 840k | 22.22 |
|
| Cogent Biosciences (COGT) | 0.8 | $17M | -40% | 450k | 38.70 |
|
| Uniqure Nv SHS (QURE) | 0.8 | $17M | +25% | 375k | 46.06 |
|
| Travere Therapeutics (TVTX) | 0.8 | $17M | 300k | 56.81 |
|
|
| Cullinan Oncology (CGEM) | 0.7 | $16M | +12% | 876k | 18.21 |
|
| Savara (SVRA) | 0.7 | $16M | 2.5M | 6.16 |
|
|
| Ideaya Biosciences (IDYA) | 0.7 | $15M | NEW | 400k | 37.27 |
|
| Perspective Therapeutics Com New (CATX) | 0.6 | $14M | +33% | 4.2M | 3.41 |
|
| Odyssey Therapeutics Common Stock (ODTX) | 0.6 | $14M | NEW | 766k | 18.71 |
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.6 | $14M | +57% | 11M | 1.24 |
|
| Omeros Corporation Put Option (OMER) | 0.6 | $13M | NEW | 1.4M | 9.51 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 0.6 | $13M | 1.3M | 10.64 |
|
|
| Equillium (EQ) | 0.6 | $13M | +234% | 4.1M | 3.20 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.6 | $13M | +48% | 148k | 85.81 |
|
| Eliem Therapeutics (CLYM) | 0.6 | $13M | +38% | 972k | 13.04 |
|
| Teva Pharmaceutical Inds Sponsored Ads | 0.6 | $13M | -73% | 374k | 33.88 |
|
| Veradermics Common Stock (MANE) | 0.6 | $12M | +42% | 100k | 122.94 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.6 | $12M | -25% | 150k | 81.51 |
|
| Omeros Corp Note 9.500% 6/1 (Principal) | 0.6 | $12M | 6.5M | 1.87 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.5 | $12M | +75% | 1.8M | 6.81 |
|
| Damora Therapeutics Com New | 0.5 | $11M | -5% | 425k | 26.01 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.5 | $11M | +3% | 1.7M | 6.61 |
|
| Vera Therapeutics Cl A (VERA) | 0.5 | $11M | 250k | 42.91 |
|
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.5 | $10M | +125% | 5.5M | 1.86 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.4 | $9.3M | 275k | 33.89 |
|
|
| Korro Bio (KRRO) | 0.4 | $9.3M | 707k | 13.18 |
|
|
| Anteris Technologies Global (AVR) | 0.4 | $9.0M | 912k | 9.85 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $8.6M | -42% | 1.5M | 5.90 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.4 | $8.0M | NEW | 30k | 266.72 |
|
| Ibio Com New (IBIO) | 0.3 | $7.0M | +28% | 4.0M | 1.75 |
|
| Generate Biomedicines Com Shs (GENB) | 0.3 | $6.7M | +14% | 400k | 16.87 |
|
| Evommune Com Shs Put Option (EVMN) | 0.3 | $6.6M | NEW | 500k | 13.29 |
|
| Tyra Biosciences (TYRA) | 0.3 | $6.4M | -22% | 200k | 31.94 |
|
| Sol-gel Technologies Shs New (SLGL) | 0.3 | $6.3M | +142% | 85k | 74.14 |
|
| Sab Biotherapeutics Com New (SABS) | 0.3 | $5.9M | +165% | 1.5M | 3.90 |
|
| Macrogenics (MGNX) | 0.3 | $5.6M | +143% | 1.2M | 4.62 |
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.2 | $5.5M | -33% | 100k | 54.54 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.2 | $5.3M | 245k | 21.81 |
|
|
| Assembly Biosciences Com New (ASMB) | 0.2 | $5.2M | NEW | 190k | 27.48 |
|
| Rezolute Com New (RZLT) | 0.2 | $5.2M | -35% | 1.0M | 5.20 |
|
| Precision Biosciences Com New (DTIL) | 0.2 | $5.1M | +8% | 647k | 7.86 |
|
| Hemab Therapeutics Hldgs Com Shs (COAG) | 0.2 | $5.1M | NEW | 138k | 36.73 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $4.6M | 250k | 18.37 |
|
|
| Arrivent Biopharma (AVBP) | 0.2 | $4.3M | -28% | 125k | 34.74 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.2 | $4.3M | 707k | 6.12 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $4.3M | -72% | 301k | 14.15 |
|
| Mbx Biosciences (MBX) | 0.2 | $4.1M | -50% | 75k | 55.20 |
|
| Research Alliance Corp Iii Ord Shs Cl A (RACC) | 0.2 | $4.0M | NEW | 370k | 10.70 |
|
| Immunovant (IMVT) | 0.2 | $3.9M | 100k | 38.53 |
|
|
| Amanat Acquisition Corp Cl A Ord (AMAN) | 0.2 | $3.8M | NEW | 375k | 10.16 |
|
| Biohaven (BHVN) | 0.2 | $3.7M | NEW | 250k | 14.88 |
|
| Faeth Therapeutics Com New (FTH) | 0.2 | $3.6M | NEW | 144k | 25.00 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $3.1M | -37% | 313k | 9.77 |
|
| Alector (ALEC) | 0.1 | $3.0M | +202% | 1.5M | 2.01 |
|
| Spyglass Pharma Com Shs (SGP) | 0.1 | $2.9M | -47% | 132k | 22.26 |
|
| Crinetics Pharmaceuticals In | 0.1 | $2.8M | 75k | 37.42 |
|
|
| Oaktree Acquisition Corp Iii Unit 10/04/2029 (OACCU) | 0.1 | $2.8M | 250k | 11.00 |
|
|
| Celcuity Note 0.250% 8/0 (Principal) | 0.1 | $2.3M | NEW | 2.0M | 1.14 |
|
| Jatt Ii Acquisition Corp Ord Shs (JATT) | 0.1 | $2.3M | NEW | 200k | 11.36 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $1.8M | NEW | 1.1M | 1.70 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $1.8M | NEW | 99k | 17.96 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.1 | $1.8M | -6% | 154k | 11.50 |
|
| Spruce Biosciences Com New (SPRB) | 0.1 | $1.6M | NEW | 30k | 54.00 |
|
| Summit Therapeutics Call Option (SMMT) | 0.1 | $1.5M | NEW | 100k | 14.57 |
|
| Eikon Therapeutics (EIKN) | 0.1 | $1.3M | NEW | 98k | 13.05 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.0 | $1.1M | 241k | 4.56 |
|
|
| Engene Therapeutics (ENGN) | 0.0 | $1.0M | NEW | 600k | 1.73 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.0 | $677k | 145k | 4.67 |
|
|
| Boundless Bio (BOLD) | 0.0 | $625k | NEW | 250k | 2.50 |
|
| Lenz Therapeutics (LENZ) | 0.0 | $568k | 100k | 5.68 |
|
|
| Q32 Bio (QTTB) | 0.0 | $354k | 28k | 12.74 |
|
|
| Health Sciences Acq Corp 2 (OBIO) | 0.0 | $144k | -91% | 33k | 4.32 |
|
| Nextcure Com New (NXTC) | 0.0 | $67k | -82% | 42k | 1.60 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $52k | 80k | 0.65 |
|
|
| Rocket Pharmaceuticals *w Exp 09/02/202 | 0.0 | $277.500000 | 75k | 0.00 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2026 Q2 filed Aug. 13, 2026
- Affinity Asset Advisors 2026 Q1 filed May 14, 2026
- Affinity Asset Advisors 2025 Q4 filed Feb. 13, 2026
- Affinity Asset Advisors 2025 Q3 filed Nov. 13, 2025
- Affinity Asset Advisors 2025 Q2 filed Aug. 13, 2025
- Affinity Asset Advisors 2025 Q1 filed May 14, 2025
- Affinity Asset Advisors 2024 Q4 filed Feb. 13, 2025
- Affinity Asset Advisors 2024 Q3 filed Nov. 13, 2024
- Affinity Asset Advisors 2024 Q2 filed Aug. 14, 2024
- Affinity Asset Advisors 2024 Q1 filed May 14, 2024
- Affinity Asset Advisors 2023 Q4 filed Feb. 13, 2024
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023